Big Pharma Deals Send Dow Lower

On a day when the Department of Labor issued a seemingly great jobs report, the Dow Jones Industrial Average (DJINDICES: ^DJI  )  was off 0.28% late in trading. A big reason is the index's two big pharma companies, Merck (NYSE: MRK  ) and Pfizer (NYSE: PFE  ) , falling as acquisition and sale rumors swirl.

The U.S. economy added 288,000 jobs in April, the most since January 2012. Unemployment fell to 6.3% as the labor force shrank by 806,000 people, a surprise number that should be taken with a grain of salt. Over the long term, the labor force will shrink as workers retire and there are fewer young people to replace them in the labor force. Still, that's a huge number and there's probably a lot of seasonality after a long winter.

Overall, more jobs is good for the economy and that should be the takeaway today.

Big Pharma holding back the Dow
Merck was the biggest Dow decliner today, falling 2.5% as of 3:30 p.m. EDT. The company is ending its trial for an ovarian cancer treatment it was testing with Endocyte after the drug failed to meet the companies' efficacy goals. The independent Data Safety Monitoring Board recommended that they stop the trial, and Merck will take on manufacturing costs related to the drug. In the grand scheme, this isn't a deal breaker for Merck, but it's a disappointing result nonetheless.  

There are also reports that Merck is near a $14 billion deal to sell its consumer unit to Bayer. Management has said it wants to sell some assets to increase operating leverage, and peeling off the consumer business will be a piece of that.  

Pfizer's headquarters will be busy with the AstraZeneca bid and may not be headquarters for long.

Elsewhere in pharma deal-making circles, AstraZeneca has reportedly rejected Pfizer's $106 billion acquisition billion bid. Pfizer is trying to acquire AstraZeneca's cancer treatment pipeline, and could move its headquarters to London in an effort to save on taxes as well.  

Pfizer has been pursuing the deal for months, but AstraZeneca CEO Pascal Soriot said the refreshed offer doesn't adequately pay the company for its new drug pipeline. If the AstraZeneca board doesn't change its mind, or the offer isn't increased, Pfizer could take the proposal straight to shareholders in a hostile takeover. That's a long, costly process that Pfizer wants to avoid, and the standoff is one reason shares are down 1.5% today.

This won't be a quick process, but Pfizer shareholders should hope a deal can be completed seamlessly. It would add important drugs to Pfizer's fading pipeline and save the company money on taxes. Only time will tell how this one plays out.

Will this stock be your next multibagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2941687, ~/Articles/ArticleHandler.aspx, 10/30/2014 9:44:11 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement